Any violation observed within the Etablissement français du sang, and caused by it, of the legislative or regulatory requirements applicable to it, as well as the elements mentioned in article L. 1222-11 or the terms of any approval or authorisation decision provided for by this code, may result in the temporary or permanent modification or withdrawal of the approval or authorisation.
Modification or withdrawal by the Director General of the Agence nationale de sécurité du médicament et des produits de santé may only take place after formal notice has been given to the President of the Etablissement français du sang to take all appropriate measures to remedy the breach or failure observed or to provide all necessary explanations.
In the event of an emergency relating to the safety of individuals, the approval or authorisation may be suspended as a precautionary measure by the Director General of the Agence nationale de sécurité du médicament et des produits de santé.